Actavis PLC (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) are close to a merger deal, according to The Wall Street Journal. The reported price for Allergan is $210 to $220, according to sources.
A deal between the two pharmaceutical companies would make it nearly impossible for Valeant Pharmaceuticals and investor Bill Ackman to takeover the combined company.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The announcement of a merger deal could come as early as Monday, reports persons familiar with the matter.
Actavis closed Friday at $243.77, a gain of $2.14 (0.89 percent), while Allergan shares gained $2.44 (1.24 percent) to close at $198.65.